ARGX Latest Press Releases

-- January 13, 2026 --

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG Globe Newswire 1:00 AM

-- January 12, 2026 --

argenx Highlights 2026 Strategic Priorities Globe Newswire 1:00 AM

-- January 6, 2026 --

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 1:00 AM

-- January 5, 2026 --

argenx Announces Leadership Transition Marking Next Evolution of Growth Globe Newswire 1:00 AM

-- December 15, 2025 --

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease Globe Newswire 1:00 AM

-- November 18, 2025 --

argenx Announces Results of Extraordinary General Meeting of Shareholders Globe Newswire 4:01 PM

-- October 30, 2025 --

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update Globe Newswire 2:00 AM

-- October 29, 2025 --

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients Globe Newswire 11:00 AM

-- October 23, 2025 --

argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 Globe Newswire 1:00 AM

-- October 15, 2025 --

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session Globe Newswire 1:00 AM

-- October 3, 2025 --

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software